REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT (Q2035362)

From EU Knowledge Graph
Revision as of 14:34, 15 July 2020 by DG Regio (talk | contribs) (‎Changed an Item)
Jump to navigation Jump to search
Project in Italy financed by DG Regio
Language Label Description Also known as
English
REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT
Project in Italy financed by DG Regio

    Statements

    0 references
    423,871.16 Euro
    0 references
    847,742.32 Euro
    0 references
    50.0 percent
    0 references
    13 December 2016
    0 references
    6 July 2019
    0 references
    ISTITUTI FISIOTERAPICI OSPITALIERI - IFO
    0 references
    TAKIS SRL
    0 references
    ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI
    0 references
    0 references
    0 references
    0 references
    0 references

    41°53'35.95"N, 12°28'58.55"E
    0 references
    REVER3MAB: UN ANTICORPO MONOCLONALE DIRETTO CONTRO LA PROTEINA ERBB3 IN GRADO DI BLOCCARE LA PROLIFERAZIONE DELLE CELLULE TUMORALI IN VITRO E IN VIVO, CON POTENZIALE USO COME AGENTE TERAPEUTICO IN CLINICA. (Italian)
    0 references
    REVER3BAB: A MONOCLONAL ANTIBODY AGAINST THE ERBB3 PROTEIN CAPABLE OF BLOCKING IN VITRO AND IN VIVO CANCER CELLS, WITH POTENTIAL USE AS A THERAPEUTIC AGENT IN CLINICAL USE. (English)
    0 references

    Identifiers

    F87H18000370007
    0 references